Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female (of nonchildbearing potential, practicing total abstinence, sexually active with female partners only, or using allowed contraceptive methods) at least 18 years of age at time of screening.~* Screening laboratory result indicating HCV GT3 infection.~* Chronic HCV infection, defined as one of the following:~  * Positive for anti-HCV antibody (Ab) or HCV RNA at least 6 months before screening; or~ * A liver biopsy consistent with chronic HCV infection; or~ * Abnormal alanine aminotransferase (ALT) levels for at least 6 months before screening.~* Hepatitis C virus treatment-naïve (i.e., participant had never received any anti-HCV treatment).~* Documented as noncirrhotic.~Exclusion Criteria:~* Female who was pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner was pregnant or planning to become pregnant during the study.~* Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could have precluded adherence to the protocol in the opinion of the investigator.~* Positive test result at screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus Ab (HIV Ab).~* Hepatitis C virus genotyping performed during screening indicated co-infection with more than one HCV genotype.~* Any cause of liver disease other than chronic HCV infection.~* Consideration by the investigator, for any reason, that the participant was an unsuitable candidate to receive ABT-493/ABT-530, SOF, or DCV.~* History of severe, life-threatening, or other significant sensitivity to any excipients of the study drug.~* Previous use of any anti-HCV treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
- Arm B (Type: ACTIVE_COMPARATOR): Sofosbuvir 400 mg once daily (QD) co-administered with daclatasvir 60 mg QD for 12 weeks.
- Arm C (Type: EXPERIMENTAL): ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).